CD274 and neoplasm: It has been well established that blocking the interaction between programmed death-1 (PD-1) and its ligand PD-L1 reinvigorates dysfunctional tumor-infiltrating effector T cells to overcome adaptive immune resistance and enhance antitumor activity [3–5].